AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

Navigating the drug manufacturing world requires balancing patent cliffs against fresh pipelines. Choosing between AbbVie (NYSE:ABBV) and Bristol Myers Squibb (NYSE:BMY) in 2026 involves weighing steady growth against deep value in a shifting landscape.

AbbVie has transitioned from its reliance on a single blockbuster to a multi-pronged approach in immunology and aesthetics. Bristol Myers Squibb remains a leader in oncology and cardiovascular health, currently focusing on refreshing its portfolio after major acquisitions. Both companies are staples for dividend seekers, but their paths to future earnings estimates differ significantly for investors today.

The case for AbbVie

AbbVie operates as a global biopharmaceutical giant focused on complex diseases through segments like immunology, oncology, and aesthetics. Its strategy centers on scaling newer blockbusters to replace older ones, selling primarily to large wholesalers and government agencies. In its latest annual report, the company noted that three major U.S. wholesale distributors, McKesson (NYSE:MCK), Cardinal Health (NYSE:CAH), and Cencora (NYSE:COR), account for nearly all of its domestic pharmaceutical sales.

In FY 2025, revenue reached nearly $61.2 billion, representing growth of approximately 8.6% compared to the prior year. This growth is notable as the company continues to navigate the evolving market for pharmaceutical stocks while managing the transition away from its historically largest product. Net income for the period was roughly $4.2 billion, illustrating the company's ability to remain profitable while investing in its next generation of treatments.

As of its December 2025 balance sheet, the company reported a debt-to-equity ratio of -21.1x, which means total liabilities exceed shareholder equity. The current ratio stands at approximately 0.7x, which measures a company's ability to pay short-term obligations with short-term assets. Free cash flow reached roughly $17.8 billion during the year. This figure, calculated by subtracting capital expenditures from operating cash flow, represents the actual cash available to pay dividends or reduce debt.

The case for Bristol Myers Squibb

Bristol Myers Squibb focuses on delivering innovative medicines for serious diseases, with a heavy emphasis on oncology and cardiovascular health. The company sells its products globally to wholesalers and specialty pharmacies, while also maintaining direct-to-patient offerings for select products. In its latest annual report, the company highlighted a 2025 U.S. Government Agreement to provide discounted prices to Medicaid and other patients. Its strategy involves a mix of internal development and strategic acquisitions to bolster its portfolio of treatments for chronic conditions.

In FY 2025, revenue reached approximately $48.2 billion, which was roughly flat with a slight decrease of 0.2% compared to the previous fiscal year. Despite the stagnant revenue growth, the company reported a healthy net income of nearly $7.1 billion. This reflects a net margin of approximately 14.6%, which is a measure of how much profit a company keeps for every dollar of revenue earned. This level of profitability remains a core draw for investors looking for stability in the healthcare sector.

As of its December 2025 balance sheet, the debt-to-equity ratio is roughly 2.6x. This ratio compares a company's total debt to its shareholder equity to show how much of the business is financed by creditors. The current ratio is approximately 1.3x, suggesting the company has more than enough short-term assets to cover its upcoming bills. Free cash flow for the year was nearly $12.8 billion, providing ample capital for the company to support its dividend payments and internal research initiatives.

Risk profile comparison

AbbVie faces significant revenue concentration, as two major drugs currently account for approximately 42% of its total net revenues. This creates vulnerability if those products face unexpected safety issues or increased competition. The company also deals with pricing pressures from the Inflation Reduction Act, which allows for government-set drug prices. Furthermore, ongoing generic competition and the high failure rate of research and development projects remain constant threats to its long-term revenue stability.

Bristol Myers Squibb carries risks related to its reliance on legacy products like Eliquis and Opdivo, which eventually face the loss of market exclusivity. The company is currently involved in a revived $6.7 billion lawsuit regarding its acquisition of Celgene, adding significant legal uncertainty. It also faces patent disputes with companies like Cytokinetics (NASDAQ:CYTK) and pricing pressures from European cost-containment measures. Additionally, the recent termination of a manufacturing partnership highlights the execution risks involved in maintaining complex cell therapy production strategies.

Valuation comparison

Bristol Myers Squibb appears significantly cheaper on its Forward P/E and P/S ratio than AbbVie, which commands a premium.

Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?

I'd go with AbbVie. Its immunology franchise is operating at a level that is difficult to match anywhere in pharma right now. Skyrizi and Rinvoq are each growing at a pace that keeps pushing management to raise its full-year outlook, and the revenue hit from cheaper competing versions of Humira entering the market is mostly behind the company now. The company has a neuroscience portfolio is adding an interesting second major growth engine to an already profitable business. And a growing dividend makes the wait more comfortable for patient investors.

Bristol Myers Squibb has made positive strides, with its newer growth brands gaining traction and some interesting candidates in the pipeline. The stock is cheap, and for good reason. Investors have already priced in a lot of the difficulty ahead, which softens the downside but does not make it an obvious buy right now.

I like that AbbVie has already navigated its toughest stretch and has kept growing through it. Bristol Myers Squibb is still working through its version of that same challenge, and the timeline for recovery is hard to predict. For a patient investor who wants pharmaceutical exposure today rather than a bet on when BMY turns the corner, AbbVie is the clearer choice.

Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie, Bristol Myers Squibb, and Cytokinetics. The Motley Fool recommends McKesson. The Motley Fool has a disclosure policy.